Your session is about to expire
← Back to Search
Novel Combination Therapy for B-Cell Lymphoma
Study Summary
This trial is testing a new drug to see what the highest dose is that can be tolerated without causing severe side effects. The new drug is being tested in combination with standard drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 4 trial • 122 Patients • NCT01474915Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a serious stomach or intestinal bleed in the last month.I have not received any live vaccines in the last 4 weeks.I have not started any new treatments in the last two weeks.I have not taken steroids to treat cancer in the last 7 days.I have been diagnosed with a specific type of lymphoma or my previous lymphoma has transformed into a more aggressive form.My previous cancer treatment followed a standard schedule.I have not had radiation therapy in the last 28 days.I have recovered from side effects of my last cancer treatment.I can care for myself but may not be able to do heavy physical work.I do not have serious heart conditions like uncontrolled chest pain or heart failure.I am not on any other cancer treatments except for supportive care medications.My aggressive B-cell lymphoma didn't respond or got worse after one treatment.I do not have active HIV, Hepatitis B, or C, or any uncontrolled infection. I may have had Hepatitis but it's now under control.I have waited long enough for my previous medication to wear off.I have another cancer, but it won't affect this trial's treatment.I am 16 years old or older.I haven't taken any biologic agents like monoclonal antibodies in the last 28 days.I am under 65 and considered fit for intensive chemotherapy and a stem cell transplant.My heart's pumping ability is below 40%.I have not had a stroke or heart attack in the last 3 months.You cannot participate if you are allergic to the study drugs or any of their ingredients.My kidney function, measured by creatinine or GFR, is within the required range.I am not pregnant, breastfeeding, and if capable of childbearing, I agree to use birth control during the study.I am using or will use effective birth control during and after treatment.My cancer can be measured by scans taken within the last 28 days.I do not have active brain or spinal cord disease, or if I did, it's now under control.I have had up to 3 treatments for my transformed low-grade lymphoma.
- Group 1: Tafasitamab + R-GDP
- Group 2: Glofitamab + R-GDP
- Group 3: Venetoclax + R-GDP
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the research team require additional volunteers for this experiment?
"Affirmative. This clinical trial, which was initially uploaded on December 6th 2019 is still actively recruiting participants and saw its most recent update occur on January 24th 2022. 18 individuals are being sought across 3 different locations."
What maladies is RiTUXimab Injection commonly used to address?
"Patients with ophthalmia, sympathetic and branch retinal vein occlusion, or advanced testicular cancer may find relief by undergoing RiTUXimab Injection."
Are there any additional experiments involving RiTUXimab Injection that have been published?
"The National Institutes of Health Clinical Center, 9000 Rockville Pike was the first to research RiTUXimab Injection in 1993. Since then there have been 3462 clinical trials completed and with 2039 still underway; many of these being carried out from Vancouver, British Columbia."
What is the uppermost limit for participants in this trial?
"This medical trial requires 18 enrollees that meet the established admission criteria. Potential participants can join this study in various locations such as BCCA - Vancouver Cancer Centre and The Jewish General Hospital, both located in Canada."
Am I eligible to join this research project?
"Eligibility requirements for this trial dictate that applicants must suffer from b-cell lymphoma and be between the ages of 16 and 65. This medical study is currently accepting 18 participants in total."
Are any individuals below the age of 70 able to participate in this research?
"This trial has established the age range from 16 to 65, with all patients falling within this bracket eligible for enrollment."
Share this study with friends
Copy Link
Messenger